Abstract: Disclosed herein is a different and novel approach to cancer vaccines using a subject's own dendritic cells (DCs) and macrophages (Mphs) in combination to present cancer antigens to the immune system. Further disclosed are methods of producing monocyte-derived autologous DCs and Mphs loaded ex vivo with particular whole irradiated cancer cells which generates optimally activated immunostimulatory antigen-presenting cells (APCs) as a superior method for stimulating robust and long-lasting immunity to a particular cancer in vivo as compared with more traditional vaccination methods. Compositions, methods of use and methods for preparation of these DCs and Mphs with cancer cells are also disclosed herein.

Abstract: Disclosed herein is a different and novel approach to cancer vaccines using a subject's own dendritic cells (DCs) and macrophages (Mphs) in combination to present cancer antigens to the immune system. Further disclosed are methods of producing monocyte-derived autologous DCs and Mphs loaded ex vivo with particular whole irradiated cancer cells which generates optimally activated immunostimulatory antigen-presenting cells (APCs) as a superior method for stimulating robust and long-lasting immunity to a particular cancer in vivo as compared with more traditional vaccination methods. Compositions, methods of use and methods for preparation of these DCs and Mphs with cancer cells are also disclosed herein.

Abstract: Disclosed herein is a different and novel approach to cancer vaccines using a subject's own dendritic cells (DCs) and macrophages (Mphs) in combination to present cancer antigens to the immune system. Further disclosed are methods of producing monocyte-derived autologous DCs and Mphs loaded ex vivo with particular whole irradiated cancer cells which generates optimally activated immunostimulatory antigen-presenting cells (APCs) as a superior method for stimulating robust and long-lasting immunity to a particular cancer in vivo as compared with more traditional vaccination methods. Compositions, methods of use and methods for preparation of these DCs and Mphs with cancer cells are also disclosed herein.

Abstract: The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.

Abstract: The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.

Abstract: The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.

Abstract: Certain aspects of the present invention are directed to new fully human fusion partner cell lines called human Karyochi cells, and to methods for making them. Human Karyochi cells are then fused with human antibody-secreting lymphoid cells to make fully human hybridomas called Karyochi-based hybridomas, which likewise secrete fully human monoclonal antibodies. Human Karyochi cells are made by isolating a donor nucleus that is substantially free of cytoplasm from either a first malignant B-lymphocyte cell line or a normal B-lymphocyte, and transferring the donor nucleus into the cytoplasm of a recipient cell from a second T- or B-lymphoid cell line. With time the nuclei synchronize and fuse to form the chimeric Karyochi fusion partner cell line. Nuclear transfer can be accomplished using intra-cytosolic nucleus injection or by impact-induced nucleus administration.

Abstract: The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.

Abstract: The invention is directed to a new composition for making a housing block for cryosectioning comprising agarose and optimal cutting temperature medium. The invention is further directed to new methods for making a frozen section microarray of fresh non-fixed frozen cell or tissue samples that undergo only one freeze-thaw cycle before being used in a biological assay.

Abstract: Certain aspects of the present invention are directed to new fully human fusion partner cell lines called human Karyochi cells, and to methods for making them. Human Karyochi cells are then fused with human antibody-secreting lymphoid cells to make fully human hybridomas called Karyochi-based hybridomas, which likewise secrete fully human monoclonal antibodies. Human Karyochi cells are made by isolating a donor nucleus that is substantially free of cytoplasm from either a first malignant B-lymphocyte cell line or a normal B-lymphocyte, and transferring the donor nucleus into the cytoplasm of a recipient cell from a second T- or B-lymphoid cell line. With time the nuclei synchronize and fuse to form the chimeric Karyochi fusion partner cell line. Nuclear transfer can be accomplished using intra-cytosolic nucleus injection or by impact-induced nucleus administration.